Mauri, Federico
Schepkens, Corentin
Lapouge, Gaëlle
Drogat, Benjamin
Song, Yura http://orcid.org/0000-0002-1173-9172
Pastushenko, Ievgenia
Rorive, Sandrine
Blondeau, Jeremy
Golstein, Sophie
Bareche, Yacine
Miglianico, Marie http://orcid.org/0000-0001-6893-3745
Nkusi, Erwin
Rozzi, Milena
Moers, Virginie
Brisebarre, Audrey
Raphaël, Maylis
Dubois, Christine
Allard, Justine
Durdu, Benoit
Ribeiro, Floriane
Sotiriou, Christos http://orcid.org/0000-0002-5745-9977
Salmon, Isabelle
Vakili, Jalal
Blanpain, Cédric http://orcid.org/0000-0002-4028-4322
Article History
Received: 3 January 2021
Accepted: 8 October 2021
First Online: 22 November 2021
Competing interests
: C.B. is founder and advisor of ChromaCure SA, which develops drugs targeting NR2F2. J.V. and M.M. are employees of ChromaCure. C.B. owns shares in ChromaCure. The remaining authors declare no competing interests.